Drug Delivery Insight

BMI View: The use of enduring drug-delivery implants will increase in the long-term as they provide a solution to overcome the prevalent issues of non-compliance, particularly as the burden from chronic diseases increases. However, short-term pressures from cyber security, risks from leakages, and a lack of infrastructure to cater for the implementation will limit near-term uptake.

Table of Contents

1 Compliance Burden Key Driver For Drug-Delivery Implants

Corporate News

3 Agreements

3 Nucynta Deal Will More Than Double Depomed's Annual Net Product Sales

5 Vectura/Janssen Sign Deal To Develop Anti-Inflammatory Therapy

5 Seattle Genetics/BMS Enter Clinical Trial Collaboration For Adcetris/Opdivo

5 Vect-Horus/Sanofi Enter Collaboration For Neurodegenerative Diseases

5 Corporate Activities

5 Hospira Unveils Progress On Global Device Strategy

6 BioLight Invests In Newly-Formed Ophthalmic Company

Product News

6 Product Approvals

6 FDA Clears t:flex Insulin Pump With Expanded Reservoir

6 FDA Approves AbbVie's Duopa For Motor Fluctuations In Advanced PD Patients

6 La Fenice Insulin Pump Gains Re-Registration Approval In China

7 Flowonix Gains Supplemental PMA For Next-Generation Intrathecal Infusion Device

R&D

7 Medical Devices Appetite Growing For 3D Printing

8 Enrolment Begins In Tyrx Absorbable Antibacterial Envelope Trial For CIEDs Infections

8 Novartis Reports Positive Results From Phase III COPD Studies

9 First Of Three Sativex Phase III Cancer Pain Trials Misses Primary Endpoint

10 Photocure Concludes End Of Phase II Status For Cevira In US

10 Patents

10 NSAID Market Set To Welcome Encapsulated Equivalents

11 Oramed Granted Patent In Israel Covering Exenatide

11 Actavis Challenges US Abstral Patents

11 Regulatory Filings

11 Sacituzumab Govitecan Gains FDA Fast Track Designation For TNBC

12 LEO Submits NDA For Calcipotriene+Betamethasone Aerosol Foam In Plaque Psoriasis

12 Neos Submits NDA For Methylphenidate XR-ODT For ADHD